Research Article Details

Article ID: A00720
PMID: 34990079
Source: Liver Int
Title: Adherence to the dietary approaches to stop hypertension diet and non-alcoholic fatty liver disease.
Abstract: BACKGROUND AND AIMS: The evidence of the relationship between dietary approaches to stop hypertension (DASH) and non-alcoholic fatty liver disease (NAFLD) is limited. Thus, we conducted a cohort-based case-control study to examine whether adherence to the DASH diet was associated with lower NAFLD risk in China. METHODS: We included 11&#160;888 participants (2529 incident NAFLD and 9359 non-NAFLD) from the Kailuan cohort with no history of hepatitis B/C infection and alcohol drinking. DASH score was calculated based on the energy-adjusted consumption of vegetables, fruits, dairy, beans, grains, meats, fat, sodium and beverage, collected by a validated food frequency questionnaire. We used Logistic regression analysis to determine the NAFLD's risk according to the DASH score. RESULTS: Higher DASH score was associated with lower risk of NAFLD. Compared with the lowest quintile of DASH score, the highest DASH quintile had a lower risk of occurring NAFLD, with odds ratio (OR) of 0.82 (95% confidence interval [CI]: 0.70-0.96) in the multivariate model. Stratified analysis showed that the inverse association was only observed in women (OR&#160;=&#160;0.67, 95% CI: 0.48-0.94), and participants with overweight/obesity (OR&#160;=&#160;0.79, 95% CI: 0.66-0.94), fasting blood glucose <6.1&#160;mmol/L (OR&#160;=&#160;0.80, 95%: 0.67-0.96), low density lipoprotein &#8805;3.4&#160;mmol/L (OR&#160;=&#160;0.71, 95% CI: 0.53-0.96), high density lipoprotein &#8805;1.0&#160;mmol/L (OR&#160;=&#160;0.81, 95% CI: 0.69-0.96), ALT&#160;<&#160;40&#160;U/L (OR&#160;=&#160;0.79, 95% CI:0.67-0.93) and C-reactive protein &#8805;2.0&#160;mg/L (OR&#160;=&#160;0.56, 95% CI: 0.40-0.78). CONCLUSIONS: Adherence to the DASH diet was inversely associated with a lower risk of NAFLD in the Chinese population. DASH diet should be highly recommended, especially for women and people with overweight/obesity and a high CRP level.
DOI: 10.1111/liv.15156